Jason Industries, Inc. to Participate in Deutsche Bank 25th Annual Leveraged Finance Conference
/
Date26 Sep 2017
MILWAUKEE, Sept. 26, 2017 (GLOBE NEWSWIRE) — Jason Industries, Inc. (NASDAQ:JASN) (NASDAQ:JASNW) (the “Company” or “Jason”) will participate in Deutsche Bank’s 25th Annual Leveraged Finance... Read More →
CNRP Mining Announces Closing of $3,000,000 Private Placement and Amendments to Previously Closed Offerings
/
Date26 Sep 2017
VANCOUVER, British Columbia, Sept. 26, 2017 (GLOBE NEWSWIRE) — CNRP Mining Inc. (CSE:CND) (the “Company” or “CNRP Mining”), is pleased to announce that it has... Read More →
Imperial Ginseng Products Ltd. Announces Normal Course Issuer Bid
/
Date26 Sep 2017
VANCOUVER, British Columbia, Sept. 26, 2017 (GLOBE NEWSWIRE) — Imperial Ginseng Products Ltd. (TSX-V:IGP) (the “Company”) announced today that the TSX Venture Exchange (the “TSX-V”)... Read More →
Premier Exhibitions Extends Deadline for Selection of Stalking Horse Bidder In Auction of Titanic Artifacts and Other Valuable Assets
/
Date26 Sep 2017
ATLANTA, Sept. 26, 2017 (GLOBE NEWSWIRE) — Premier Exhibitions, Inc. (OTCQB:PRXIQ) the company that serves as sole legal steward of the RMS Titanic wreck site,... Read More →
Westbury Bancorp, Inc. Announces Intention to Voluntarily Delist from NASDAQ and Deregister its Common Stock
/
Date26 Sep 2017
WEST BEND, Wisc., Sept. 26, 2017 (GLOBE NEWSWIRE) — Westbury Bancorp, Inc. (the “Company”) (NASDAQ:WBB), the holding company for Westbury Bank (the “Bank”), announced today... Read More →
Argos Therapeutics Announces Appointment of Richard Morrison, PhD to Board of Directors
/
Date26 Sep 2017
DURHAM, N.C., Sept. 26, 2017 (GLOBE NEWSWIRE) — Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based... Read More →
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
/
Date26 Sep 2017
COPENHAGEN, Denmark, Sept. 26, 2017 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq:ASND), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten... Read More →
Con Edison CFO Robert Hoglund to Speak at Wolfe Research Utilities and Power Leaders Conference on September 27
/
Date26 Sep 2017
NEW YORK, Sept. 26, 2017 (GLOBE NEWSWIRE) — Robert Hoglund, senior vice president and CFO of Consolidated Edison, Inc. (NYSE:ED), will present as part of... Read More →
UPDATE: Steelcase Shapes the Smart + Connected Workplace With Microsoft Azure
/
Date26 Sep 2017
Workplace Advisor Dashboard Workplace Advisor is a cloud-enabled, space sensing network built on Microsoft Azure IoT. Steelcase Inc. Personal Assistant The Personal Assistant mobile app... Read More →
Neuralstem宣布委任两名新成员加入董事会
/
Date26 Sep 2017
马里兰州日耳曼敦, Sept. 27, 2017 (GLOBE NEWSWIRE) — 专门开发神经系统疾病创新疗法的生物制药公司Neuralstem, Inc.(纳斯达克:CUR)今天宣布,Zhang Zhuo和药学博士及公共卫生硕士Cristina Csimma已获委任加入其董事会,于2017年9月18日上任。 董事长兼首席执行官Rich Daly表示,“我热烈欢迎Zhang先生和Csimma博士加入我们的董事会。按照Tianjin Pharmaceuticals在2016年12月作出2,000万美元战略投资时的协定,Zhang作为Tianjin Pharmaceuticals的指定董事加入董事会。Tianjin去年为我们提供了强有力的支持,我们期待在我们的创新干细胞和小分子平台的研发过程中进一步加深与这家大型跨国制药企业的合作。” Daly先生续称,“Csimma博士带来了在制药行业数十年的资深领导经验以及丰富的药品开发专业知识。她在企业经营和资本筹集领域的独到见解将会在Neuralstem的潜在转型期间带来莫大的帮助。” Zhang先生于2011年加入Tianjin Pharmaceuticals,现任国际合作副总监。Zhang先生持有伦敦政治经济学院颁发的理学硕士学位,以及新西兰的University of Auckland颁发的商业经济和国际商务学士学位。 Cristina Csimma现任Exonics Therapeutics董事会的执行主席,并且也是Juniper Pharmaceuticals的董事会成员及提名和公司治理委员会的成员。她也供职于多个咨询委员会,包括Sucampo Pharmaceutical、Muscular... Read More →